Niagen Bioscience (NAGE) announced that its pharmaceutical-grade Niagen Plus products, Niagen IV and injections, are now offered at more than 50 iCRYO locations across the U.S., bringing total nationwide clinic availability to more than 900. The company stated the partnership aligns its science-backed, NAD+-boosting products with iCRYO’s clientele. “Niagen IV is now offered at over 900 clinics nationwide, including the new iCRYO locations,” stated Rob Fried, CEO of Niagen Bioscience. “This milestone highlights the growing recognition of Niagen IV and injections as essential tools for supporting healthspan.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Promising Growth and Innovation Drive Buy Rating for Niagen Bioscience
- Niagen Bioscience price target raised to $12 from $11 at H.C. Wainwright
- Niagen Bioscience’s Robust Growth and Strategic Initiatives Drive Buy Rating
- Niagen Bioscience Reports Strong Q2 Growth and Outlook
- Niagen Bioscience Reports Strong Q2 Sales Growth